Abstract
Background: The aim of this study was to investigate safety and efficacy of second-generation zotarolimus-eluting Resolute stents and everolimus-eluting Xience V stents in bifurcation lesions.
Methods: In TWENTE - a prospective, randomized DES trial - PCI patients were randomized for treatment with contemporary Resolute or Xience V stents. Clinical endpoints were adjudicated by an external independent clinical events committee (Cardialysis CRO, Rotterdam, The Netherlands). Target vessel failure (TVF; cardiac death, target vessel-related myocardial infarction, and clinically-indicated target vessel revascularization), the primary endpoint of the TWENTE trial, was assessed after 2 years.
Results: Among the 1,391 patients of the TWENTE trial, 362 (26%) patients were treated for at least one bifurcation lesion. Of these patients, 179 and 183 were randomized for treatment with Resolute and Xience V stents, respectively. At 2-year follow-up, TVF (12.8% vs. 11.5%; p=0.69) and a patient-oriented composite endpoint (17.3% vs. 16.9%; p=0.92) did not differ significantly between stent arms. In addition, rates of definite and or probable stent thrombosis were low and similar for both stent arms (0.6% vs. 0.5%; p=0.99). Within 213 (15.3%) patients, who were treated for bifurcation lesions with an additional treatment of the side-branch, there was also no significant difference in TVF between patients treated with Resolute (n=98) and Xience V (n=115) (8.2% vs. 11.3%; p=0.44).
Conclusions: Treatment of bifurcation lesions with Resolute and Xience V stents resulted in favorable and similar outcomes after 2 years in the randomized TWENTE trial.
Methods: In TWENTE - a prospective, randomized DES trial - PCI patients were randomized for treatment with contemporary Resolute or Xience V stents. Clinical endpoints were adjudicated by an external independent clinical events committee (Cardialysis CRO, Rotterdam, The Netherlands). Target vessel failure (TVF; cardiac death, target vessel-related myocardial infarction, and clinically-indicated target vessel revascularization), the primary endpoint of the TWENTE trial, was assessed after 2 years.
Results: Among the 1,391 patients of the TWENTE trial, 362 (26%) patients were treated for at least one bifurcation lesion. Of these patients, 179 and 183 were randomized for treatment with Resolute and Xience V stents, respectively. At 2-year follow-up, TVF (12.8% vs. 11.5%; p=0.69) and a patient-oriented composite endpoint (17.3% vs. 16.9%; p=0.92) did not differ significantly between stent arms. In addition, rates of definite and or probable stent thrombosis were low and similar for both stent arms (0.6% vs. 0.5%; p=0.99). Within 213 (15.3%) patients, who were treated for bifurcation lesions with an additional treatment of the side-branch, there was also no significant difference in TVF between patients treated with Resolute (n=98) and Xience V (n=115) (8.2% vs. 11.3%; p=0.44).
Conclusions: Treatment of bifurcation lesions with Resolute and Xience V stents resulted in favorable and similar outcomes after 2 years in the randomized TWENTE trial.
| Original language | English |
|---|---|
| Pages (from-to) | B61-B61 |
| Journal | Journal of the American College of Cardiology |
| Volume | 62 |
| Issue number | 18, Suppl. 1 |
| DOIs | |
| Publication status | Published - 2013 |
| Event | 25th Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics, TCT 2013 - San Francisco, United States Duration: 27 Oct 2013 → 1 Nov 2013 Conference number: 25 |
Keywords
- IR-89484
- METIS-302489